Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a research report issued on Wednesday. The brokerage set a "hold" rating on the medical research company's stock.

Several other brokerages have also issued reports on CTSO. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price target on shares of Cytosorbents in a research note on Monday, January 13th. HC Wainwright restated a "neutral" rating and set a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $4.67.

Cytosorbents Price Performance

CTSO traded up $0.02 during midday trading on Wednesday, hitting $1.01. The company had a trading volume of 113,959 shares, compared to its average volume of 485,774. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.59. The company has a market capitalization of $54.95 million, a PE ratio of -2.79 and a beta of 0.58. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The firm's 50-day simple moving average is $0.95 and its 200-day simple moving average is $1.04.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The medical research company reported ($0.09) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.03). Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The company had revenue of $9.39 million during the quarter, compared to analyst estimates of $10.14 million. During the same period in the prior year, the business earned ($0.21) EPS. Equities research analysts predict that Cytosorbents will post -0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

Several hedge funds have recently added to or reduced their stakes in CTSO. Atomi Financial Group Inc. acquired a new position in shares of Cytosorbents during the 3rd quarter worth about $51,000. Geode Capital Management LLC grew its holdings in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Finally, Sargent Investment Group LLC increased its stake in Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company's stock valued at $2,439,000 after purchasing an additional 192,747 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company's stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.